Elizabeth Smyth, MD, on New Data in Gastric/Gastroesophageal Cancers
ASCO 2026
Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses three major studies presented at this year’s meeting: the antibody-drug conjugate izalontamab brengitecan in recurrent or metasatic esophageal squamous cell carcinoma (Abstract 4008); the ATTRACTION-6 study of chemoimmunotherapy in HER2-negative advanced gastric/gastroesophageal junction (GEJ) cancer (Abstract 4006); and an investigational EP4 antagonist in combination with chemoimmunotherapy as a first-line strategy for HER2-negative gastric/GEJ cancer (Abstract 4007).
The ASCO Post Staff
Giannis S. Mountzios, MD, of Henry Dunant Hospital Center, discusses findings from a post hoc analysis of the phase III DeLLphi-304 trial, which examined the intracranial efficacy of tarlatamab vs chemotherapy as second-line therapy for small cell lung cancer (SCLC) (Abstract 8006).
Daniel A. Ermann, MD, of Huntsman Cancer Institute, University of Utah School of Medicine, presents findings from a retrospective cohort study which used a large U.S. database to evaluate clinical outcomes among Medicare beneficiaries treated with first-line therapy for chronic lymphocytic leukemia (CLL) (Abstract 7047).
To learn more about this data, read a related article in Oncology and Therapy.
The ASCO Post Staff
Kevin Kalinsky, MD, MS, FASCO, of Winship Cancer Institute of Emory University, provides an update focusing on progression-free survival after next line of treatment and subsequent therapies among patients enrolled in the ASCENT-04 trial. The study compared sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab in patients with previously untreated PD-L1–positive metastatic triple-negative breast cancer (Abstract LBA1000).
The ASCO Post Staff
Katharina C. Kaehler, MD, of University Hospital (UKSH), Campus Kiel, presents an update on the primary outcome and sensitivity analyses from the PIVOTAL phase III trial of daromun, a combination of two fibronectin-targeting immunocytokines (L19IL2 and L19TNF), as a neoadjuvant intralesional therapy in patients with resectable, locally advanced stage III melanoma (Abstract LBA9517).
The ASCO Post Staff
Asaf Maoz, MD, of Dana-Farber Cancer Institute, Mass General Brigham, and Harvard Medical School, talks about whether prospective assessment of CA 19-9 has utility as part of pancreatic cancer surveillance among high-risk individuals (Abstract 10527).
